Patexia Insight 254: Rankings of Leading ANDA Litigation Attorneys

ANDA litigation remains one of the most demanding areas of patent law, where outcomes often hinge on the experience and judgment of individual attorneys. In disputes that determine when a generic drug can enter the market, the role of lead counsel is especially critical. Some attorneys consistently handle a high volume of ANDA cases through complex procedural paths and deliver results across multiple matters.
Today’s insight highlights the top ANDA attorneys in 2025, based on measured activity and performance drawn from recent litigation data. Rather than focusing on reputation, the analysis looks at who is actively involved in ANDA disputes and how often their cases result in successful outcomes.
Key Observations From ANDA Litigation in 2025
To address the demand for clear, data-driven insights into ANDA litigation, Patexia publishes its annual ANDA Litigation Report. The 2025 edition examines the past five years of filings, stakeholders' activity, and case outcomes, highlighting the most engaged practitioners and revealing patterns that define the current state of Hatch-Waxman disputes.
Filing trends: Between July 1, 2020, and June 30, 2025, a total of 1,373 ANDA cases were filed. Annual filings increased from 246 in 2021 to 263 in 2022, remained steady at 262 in 2023, and peaked at 317 in 2024. The first half of 2025 recorded 155 cases, putting the year on track to approach 300 filings, based on the consistent monthly average of 25–27 cases seen in recent years.
Attorney activity: The report evaluated 1,574 attorneys, including 235 local counsel, who were active in at least one ANDA litigation case filed over the past five years. Each attorney was evaluated based on three measures: Activity, Success, and Performance, using Patexia’s established methodology.
Terminations and outcomes: Before the report was published, 965 ANDA cases had been resolved. Of these, 54.8% ended in dismissals (voluntary, settled, or otherwise), 31.1% concluded with a judgment, 3.5% were transferred or remanded, and the remaining cases closed administratively. This demonstrates that most Hatch-Waxman disputes are resolved without a formal court ruling.

Top ANDA Attorneys 2025
The following table highlights a selection of the top ANDA attorneys in 2025, based on their activity and performance in Hatch-Waxman litigation. These attorneys have consistently handled high volumes of cases and achieved strong outcomes, playing a central role in the most contested disputes. Being ranked among the top 30 of 1,574 attorneys places them in the top 2% of all ANDA practitioners.
| Attorney | Law Firm | All Cases | Defendant Cases | Plaintiff Cases | Rank | Category |
|---|---|---|---|---|---|---|
| Bruce M. Wexler | Paul Hastings | 30 | 1 | 29 | 1 | Paul Hastings |
| Dennies Varughese | Sterne, Kessler, Goldstein & Fox | 60 | 18 | 42 | 1 | Overall Activity Rank |
| Timothy H. Kratz | Kratz & Barry | 39 | 39 | 0 | 2 | Defendant Activity Rank |
| Andrew S. Chalson | Quinn Emanuel Urquhart & Sullivan | 13 | 0 | 13 | 3 | Plaintiff Performance Rank |
| Michael J. Gaertner | Buchanan Ingersoll & Rooney PC | 28 | 28 | 0 | 4 | Defendant Performance Rank |
| Lance A. Soderstrom | Katten Muchin Rosenman | 33 | 33 | 0 | 5 | Defendant Activity Rank |
| Seth R. Bowers | Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. | 27 | 0 | 27 | 23 | Plaintiff Activity Rank |
| William Zimmerman | Knobbe Martens | 18 | 18 | 0 | 27 | Defendant Activity Rank |
| Scott J. Bornstein | Greenberg Traurig LLP | 10 | 10 | 0 | 27 | Defendant Performance Rank |
Note: The rankings in this table and Patexia’s report are based on a combination of activity (cases handled as plaintiff, defendant, or both) and performance (success in terminated cases) metrics for all ANDA filings between July 1, 2020, and June 30, 2025. Firms are scored and ranked to reflect both their level of involvement and effectiveness in litigation. For a detailed explanation of the methodology, see our full methodology here.
Stay tuned as in the weeks ahead, we’ll turn our focus to the PTAB and CAFC, highlighting key findings from the corresponding reports published.
More insights

Patexia Insight 246: What the Latest Data Reveals About ANDA Litigation Trends
Abbreviated New Drug Application (ANDA) litigation remains one of pharma’s most contested arenas. With market exclusivity and billions in annual sales on the line, each case influences competition, pricing, and the speed at which patients see…

Patexia Insight 243: Patent Litigation Trends and Insights from the First Half of 2025
Over the past several years, patent litigation has gone through its share of ups and downs. Shifting legal standards, evolving strategies by patent owners and defendants, and broader economic factors have all played a role in defining the volume and nature…

Senator Thom Tillis Introduces Tax Bill to Curb Foreign Litigation Funding
In an effort to increase oversight and regulation of third-party litigation funding (TPLF), Senator Thom Tillis has introduced legislation that seeks to close tax loopholes currently benefiting domestic and foreign entities involved in funding U.S.…